858 Therapeutics
Angie Santini has worked in the field of science for over twenty years. Angie began their career at Merck in 1998 as a Research Biologist. In 2005, they moved to Amira Pharmaceuticals, Inc. as a Senior Research Associate. In 2011, they joined Bristol-Myers Squibb as a Senior Research Associate II and in 2012, they moved to PharmAkea as a Senior Research Associate. In 2017, they joined Jecure Therapeutics as a Scientist I and in 2019, they moved to 858 Therapeutics as a Senior Scientist.
Angie Santini earned a Bachelor of Science in Medical Microbiology & Immunology from the University of Wisconsin-Madison between 1994 and 1998.
858 Therapeutics
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response.